Details

Autor(en) / Beteiligte

• Divoux, Jordane
• Florent, Romane
• Jacobs, Margaux
• Lequesne, Justine
• Grellard, Jean-Michel
• San, Chankannira
• Grossi, Sara
• Kerdja, Katia
• Clarisse, Bénédicte
• Boudier, Gwenaelle
• Cherifi, François
• Briand, Mélanie
• Dolivet, Enora
• Johnson, Alisson
• Dubois, Brice
• Harter, Valentin
• Lacroix, Joëlle
• Raboutet, Charlotte
• Marie, Brigitte
• Rousseau, Nathalie
• Blanc-Fournier, Cécile
• Vaur, Dominique
• Figeac, Martin
• Poulain, Laurent
• Weiswald, Louis-Bastien
• Emile, George

Titel

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

Ist Teil von

• BMC cancer, 2023-09, Vol.23 (1), p.1-883, Article 883

Ort / Verlag

London: BioMed Central Ltd

Erscheinungsjahr

2023

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Background Triple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and high risk of metastasis. The current neoadjuvant treatment for TNBC consists of a regimen of immune checkpoint blocker and chemotherapy (chemo-ICB). Despite the frequent use of this combination for TNBC treatment, moderate results are observed and its clinical benefit in TNBC remains difficult to predict. Patient-derived tumor organoids (PDTO) are 3D in vitro cellular structures obtained from patient's tumor samples. More and more evidence suggest that these models could predict the response of the tumor from which they are derived. PDTO may thus be used as a tool to predict chemo-ICB efficacy in TNBC patients. Method The TRIPLEX study is a single-center observational study conducted to investigate the feasibility of generating PDTO from TNBC and to evaluate their ability to predict clinical response. PDTO will be obtained after the dissociation of biopsies and embedding into extra cellular matrix. PDTO will be cultured in a medium supplemented with growth factors and signal pathway inhibitors. Molecular and histological analyses will be performed on established PDTO lines to validate their phenotypic proximity with the original tumor. Response of PDTO to chemo-ICB will be assessed using co-cultures with autologous immune cells collected from patient blood samples. PDTO response will finally be compared with the response of the patient to evaluate the predictive potential of the model. Discussion This study will allow to assess the feasibility of using PDTO as predictive tools for the evaluation of the response of TNBC patients to treatments. In the event that PDTO could faithfully predict patient response in clinically relevant time frames, a prospective clinical trial could be designed to use PDTO to guide clinical decision. This study will also permit the establishment of a living biobank of TNBC PDTO usable for future innovative strategies evaluation. Trial registration The clinical trial (version 1.2) has been validated by local research ethic committee on December 30.sup.th 2021 and registered at ClinicalTrials.gov with the identifier NCT05404321 on June 3.sup.rd 2022, version 1.2. Keywords: Triple negative breast cancer, Patient-derived tumor organoids, Predictive functional assays, Chemo-immunotherapy